Últimas noticias sobre Catheter Precision (AMEX:VTAK) Bolsa

Catheter Precision, Inc. Common Stock

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

Catheter Precision

Mercados

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATNF

BDRX

DECK

HNRG

IMMX

INEO

INTU

LITM

LTBR

MLGO

MNSO

OKLO

ROST

SGBX

SOBR

VTAK

Intuit sorprende al mercado con ingresos y BPA mejores de lo esperado. Revisa los mayores ganadores y perdedores del premercado.

Las acciones de Intuit (INTU) cotizan un 8% más alto; Aquí están 20 acciones que se mueven en el premercado

Urban Outfitters

ATCH

BTOG

DGLY

KDLY

LTRY

LUMN

MANU

NINE

NVTS

SEDG

SNOW

UPXI

URBN

VSTE

WHLR

Longevity Health Holdings, Inc. - Common Stock

XAGE

Urban Outfitters sube tras superar expectativas de beneficios; otras acciones como Navitas y Snowflake también destacan en el premercado.

Acciones de Urban Outfitters (URBN) se disparan un 18%; Aquí están 20 acciones que se mueven en el premercado

Benchmark analyst Matthew Harrigan initiates coverage on Lionsgate Studios (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LION#NYSE">LION</a>) with a Buy rating and announces Price Target of $8.5.

Price Target

Initiation

Analyst Ratings

LION

Benchmark Initiates Coverage On Lionsgate Studios with Buy Rating, Announces Price Target of $8.5

Trial Investigates Use of Auryon Atherectomy System in Cases with Challenging Below-the-Knee Blockages
AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced enrollment of the first patient in the Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical Limb Ischemia Below-the-Knee (AMBITION BTK).
AMBITION BTK is a prospective, multicenter, randomized controlled trial (RCT) designed to investigate the clinical safety and effectiveness of the Auryon Atherectomy System combined with standard balloon angioplasty, compared to balloon angioplasty alone, in treating infrapopliteal lesions in patients with Critical Limb Ischemia (CLI). The primary endpoint will be evaluated using a win-ratio approach, comparing the two treatment groups based on the following components in a hierarchical manner at 12 months: freedom from major amputation, freedom from clinically driven target lesion revascularization (CD-TLR), and primary patency.
The RCT will include up to 224 patients at up to 30 sites. In parallel, a companion registry will enroll up to 1,500 additional patients who are ineligible for the RCT and are treated with the Auryon System above or below the knee.

ANGO

AngioDynamics Enrolls First Patient In Randomized Study Of AMBITION Below-the-Knee

ORIS

Oriental Rise Holding Signs Non-Binding Letter Of Intent to Acquire 100% Equity Interests Of Fujian Daohe Tea Technology And Ningde Minji

VisionWave Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWAV#NASDAQ">VWAV</a>) ("VisionWave" or the "Company"), a next-generation defense technology company, today announced that it has entered into a transformative funding agreement with a prominent institutional investor, securing an equity line for up to $50 million in capital through a Standby Equity Purchase Agreement (SEPA), along with a $5 million tranche funding commitment in the form of convertible notes.
This financing empowers VisionWave to execute on the strategic initiatives outlined in its investor presentation including the scaled deployment of its AI-powered multi-domain defense solutions across autonomous aerial, ground, and maritime systems.
Under the terms of the agreement, VisionWave has the right to sell up to $50 million in common stock over a 24-month period at its discretion, providing flexible, growth-focused capital. The investor also committed to funding $5 million through convertible notes to support immediate scaling efforts, of which, the first $3 million was funded upon entering into the funding agreement.
Importantly, the $5 million tranche funding includes protective covenants which prohibit the use of proceeds to pay any pre-existing liabilities accrued before the Company's business combination. This ensures that all capital raised is strictly designated for working capital and growth initiatives, reinforcing VisionWave's forward-focused strategy.

Financing

VWAV

VisionWave Secures Up To $55M In Growth Capital To Scale AI Defense Solutions, Including $50M Equity Line And $5M In Convertible Notes

Buybacks

General

BMRC

Bank Of Marin Bancorp Has Authorized Repurchase Of Up To $25M OF Its Common Stock Through July 31, 2027

JP Morgan analyst Matthew Boss maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Overweight and raises the price target from $355 to $406.

JP Morgan Maintains Overweight on Ralph Lauren, Raises Price Target to $406

Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) (the "Company"), owner of Bed Bath &amp; Beyond, Overstock, buybuy BABY, and a blockchain asset portfolio, today announced that it has sent a follow-up letter to tZERO's management and Board of Directors urging it, as tZERO's largest equity holder, to take specific and prioritized actions to unlock value and capitalize on the present favorable market conditions.
A Follow-Up Letter to tZERO Board of Directors:
Dear Members of the Board of Directors,
Further to the letter I sent last week, I want to double down on what I said, tZERO has all the foundational ingredients to lead the digital assets space in the U.S. The licenses, IP, and early market position are there. But now it's about execution.
We believe the company is at a pivotal point. To unlock the full value and capitalize on the growing institutional and regulatory momentum, we need to move quickly and deliberately. As the largest equity holder of tZERO, here are the actions we strongly recommend and would like to see prioritized:
<ul>
<li>File a shelf registration or consider leveraging Beyond as a public platform using its existing infrastructure. Either path can provide the flexibility needed for capital raises, M&amp;A activity, and broader strategic execution. The goal is to create optionality and remove constraints to growth.</li>
<li>Restructure the board by bringing in individuals with real operating and regulatory experience in digital assets. The current opportunity requires sharper, more specialized governance.</li>
<li>Find global partners who can actively drive deal flow and contribute real-world assets to the platform and give them clear incentives to help grow it. That incentive needs to go beyond just unlocking the value of their own assets. It should include true upside: where their activity helps grow the ecosystem, they participate in the value creation of the platform itself.</li>
<li>Advance the Layer 2 strategy, but only with partners who are ready to execute now. This must be tied directly to onboarding meaningful RWA volume and building usage from day one.</li>
<li>Launch a full-scale marketing and PR initiative that elevates tZERO's public presence and clearly communicates the differentiated value of our technology stack, including the Proof platform and the MAP (Marketplace Asset Protocol) infrastructure. These are meaningful assets, and we need the market to know it.</li>
<li>Convert TZROP into equity. As the largest TZROP holder, we see far more long-term value in exchanging our revenue rights for equity in the company. We believe that a conversion at fair value would simplify the cap structure, align incentives across stakeholders, and give the company significantly more flexibility to raise capital, pursue partnerships, and execute on its roadmap. This is a critical step toward creating clarity and momentum.</li>
</ul>
Some of this may already be under discussion, and that's good. But we're urging you to take clear, visible action now. There's a moment here, and we don't want to look back and say we missed it.
We're fully behind you, and we're here to help. Let's get moving.
Best, /s/ Marcus
Marcus Lemonis Executive Chairman, Beyond, Inc.

Management

BYON

Beyond Urges tZERO To Accelerate Growth Strategy, Calls For Board Restructure, Capital Flexibility, And Equity Conversion To Unlock Value

Several Esteemed Cancer Centers to Commence Patient Enrollment Before the End of September
The Registry Study, Known as PanTheR, will Expand the Safety and Performance Data of the FDA-Cleared RenovoCath&#xAE; Device, and its Associated Survival Outcomes in Patients Diagnosed with Solid Tumors
Cancer Centers in the Registry Study will Purchase RenovoCath Devices from RenovoRx
RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, today announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461).
The initiation of this study demonstrates RenovoRx's commitment to innovation and RenovoCath's current and future potential. The study will serve as a critical tool for understanding RenovoCath's safety and effectiveness in a real-world setting, providing valuable insights into long-term effectiveness and patient outcomes. Patient enrollment is expected to commence before the end of September 2025. Each cancer center participating in the registry study will purchase RenovoCath devices for use in the study from RenovoRx.
A registry study, or post-approval study, is a clinical study that involves collecting data on the long-term use and performance of a medical device, such as RenovoCath, after it has been cleared for market by the FDA. PanTheR is a multi-center, post-marketing observational registry study designed to evaluate the long-term safety of and survival outcomes for patients diagnosed with solid tumors who are treated using RenovoCath for targeted drug delivery. PanTheR will capture real-world data on the utilization of RenovoCath and generate additional safety information across a broader range of solid tumors. This data may be used to inform future clinical trial designs.
The first of multiple clinical sites to initiate patient enrollment in the PanTheR study is the University of Vermont (UVM) Cancer Center, with Dr. Conor O'Neill, Assistant Professor at the UVM Larner College of Medicine and surgical oncologist at the UVM Medical Center, serving as Principal Investigator. Additional clinical sites in the post-marketing registry study are expected to initiate enrollment soon.

RNXT

RenovoRx Launches PanTheR Post-Marketing Registry Study, To Expand Safety And Performance Data Of FDA-Cleared RenovoCath Device, And Associated Survival Outcomes In Patients Diagnosed With Solid Tumors

Jim Cramer has predicted that Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) will soar to $200, following its recent surge past $150.
Check out the <a href="https://www.benzinga.com/quote/PLTR">PLTR stock price here</a>.
What Happened: In a post on X, CNBC&#8217;s &#8216;Mad Money&#8217; host Cramer described the stock's upward movement as "like a knife through butter," signaling a bullish outlook on the AI-driven data analytics firm.
Palantir, known for its Gotham and Foundry platforms used by U.S. defense and commercial sectors, hit a fresh record high of $160.39 per share intraday on Friday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Palantir being pushed up nicely. Right through $150 like a knife through butter. Next stop: $200. Obviously Robinhood roaring, too
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1949764867268784395?ref_src=twsrc%5Etfw">July 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Last week, the U.S. Army awarded a $100 million contract to the Anduril-Palantir team for the delivery of a Next-Generation Command and Control (NGC2) platform prototype.
With this deal, Palantir is poised to secure an estimated $30 million from an 11-month contract, a high-priority U.S. Army project, <a href="https://www.insidermonkey.com/blog/palantir-pltr-wins-key-u-s-army-ai-contract-in-push-for-defense-growth-1573150/">reported</a> Insider Monkey, citing William Blair analyst Louie DiPalma. 
This initiative also offers the potential to boost Palantir&#8217;s annual recurring revenue by over $150 million within three years.
Wedbush analyst Dan Ives also highlighted Palantir as a key beneficiary of President Donald Trump&#8216;s &#8220;<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46580004/trumps-ai-action-plan-to-unleash-4th-industrial-revolution-dan-ives-picks-6-stock-winners">AI Action Plan</a>,&#8221; which aims to secure U.S. leadership in the sector, and he also listed it as one of his <a href="https://www.benzinga.com/markets/equities/25/07/46463595/dan-ives-picks-5-stocks-for-2nd-half-of-2025-nvidia-palantir-microsoft-and-more-golden-age-of-tech-is-here-with-ai-revolution">top five picks</a> for the second half of 2025. 
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46655759/these-3-dividend-yielding-stocks-could-outperform-as-high-fed-rates-spark-4-9-billion-inflows-ex">These 3 Dividend-Yielding Stocks Could Outperform As High Fed Rates Spark $4.9 Billion Inflows: Expert</a>
Why It Matters: Additionally, last week on Friday, Piper Sandler analyst Brent Bracelin announced a <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46635102/palantir-technologies-stock-hits-a-new-all-time-high-whats-driving-the-action">$170 price target</a> for Palantir. 
This followed Ives&#8217; target price <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46339022/palantir-could-be-the-next-big-ai-winner-says-dan-ives-sees-12-pltr-stock-surge">increase to $160 apiece</a>, underlining the growing confidence in Palantir&#8217;s artificial intelligence strategy. He described PLTR to be on a &#8220;golden path to become an AI stalwart&#8221; over the next 12 months. 
The enthusiasm of various analysts underscores their belief in the company&#8217;s potential to dominate the AI landscape, despite its forward P/E ratio of 277.778, raising valuation concerns among some investors.
While bullish analysts like Ives and Bracelin are raising their targets, the broader analyst consensus of 25 experts, as <a href="https://www.benzinga.com/quote/PLTR/analyst-ratings">tracked by Benzinga</a>, remains a &#8216;Sell&#8217; with an average price target near $80.6. Despite this, investor sentiment, propelled by key government contracts and strategic enterprise partnerships, continues to drive the stock to new heights.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/PLTR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="387" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071416/PLTR-ANR-new-fresh-latest-1024x387.png" alt="" class="wp-image-1003078" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071416/PLTR-ANR-new-fresh-latest-1024x387.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071416/PLTR-ANR-new-fresh-latest-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071416/PLTR-ANR-new-fresh-latest-768x290.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071416/PLTR-ANR-new-fresh-latest.png 1098w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Price Action: Palantir was up 1.41% in premarket on Monday. It has risen by 111.20% on a year-to-date basis and 486.41% over the past year.
Benzinga's Edge Stock Rankings indicate that PLTR maintains solid momentum across short, medium, and long-term periods. However, while the stock scores well on growth rankings, its value rating remains relatively weak. Additional performance details are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-3/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-3/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="155" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071351/edge-new-PLTR-1024x155.png" alt="" class="wp-image-1003076" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071351/edge-new-PLTR-1024x155.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071351/edge-new-PLTR-300x46.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071351/edge-new-PLTR-768x116.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071351/edge-new-PLTR.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Monday. The SPY was up 0.18% at $638.23, while the QQQ advanced 0.37% to $568.47, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46653560/bitcoin-ethereum-ripple-have-big-money-moment-as-expert-sees-incremental-institutional-buyers-driving-current-rally" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Ripple Have ‘Big Money' Moment As Expert Sees ‘Incremental Institutional Buyers' Driving Current Rally</a></li>
</ul>
Image via Shutterstock

PLTR

Palantir's Next Stop Is $200, Says Jim Cramer As PLTR Glides 'Like A Knife Through Butter'

LOBO

LOBO EV Technologies And Strattners Explore Strategic Investment Partnership

- IsoBio,&nbsp;Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked and novel tumor antigens for patients in need of new cancer therapies. &nbsp;
- IsoBio has closed its initial Series Seed financing round, raising $5 million from ASP&nbsp;Isotopes&nbsp;Inc. (ASPI).
- The strategic collaboration contemplates future manufacturing opportunities for PET&nbsp;Labs (ASPI's nuclear medicine subsidiary).
- IsoBio plans to leverage the technology and global manufacturing capabilities developed by ASPI to reduce the uncertainty of isotope supply chain/manufacturing, and develop novel isotopes for radiotherapeutics.
- IsoBio was co-founded and is led by Bruce Turner, M.D., Ph.D., CEO and President, and will establish its offices in Seattle, WA and Gladwyne, PA.
- IsoBio management team to host investor call for ASPI investors on Wednesday July 30th at 10am EST. See below for dial in details.
WASHINGTON and SEATTLE and GLADWYNE, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it has completed an initial Series Seed financing round of IsoBio, a U.S.-based radiotherapeutic development company. IsoBio plans to use the capital raised to develop potent targeted therapies for cancer patients using monoclonal antibodies against derisked and validated tumor antigens, as well as novel tumor targets, that will be combined with highly active novel isotopes to produce much-needed new treatments.
For the successful development and commercial supply of radiotherapeutics, the supply chain is critical and in recent years there have been many examples where the clinical development and commercial progress of radiotherapies have been constrained by limited supply of the required commonly used isotopes. The strategic partnership between IsoBio with ASP Isotopes Inc(including its nuclear medicine subsidiary, PET Labs) should reduce the uncertainty of the isotope supply chain and provide IsoBio with a significant advantage over other biotechnology companies trying to develop novel targeted radiotherapies particularly as some of the complex isotopes become tailored for the treatment of specific tumors and are not available for development.
IsoBio is developing radiotherapeutics containing Lutetium-177, Actinium-225, Terbium-161, and other undisclosed novel radioisotopes, which will be attached to antibodies using novel proprietary linker and conjugation technology to create highly potent antibody-isotope conjugates (AICsTM). AICs will provide a highly targeted approach for difficult to treat tumors allowing for maximal efficacy while minimizing off-target toxicity.

ASPI

IsoBio Closes $5M Seed Round Led By ASP Isotopes To Advance Antibody-Isotope Cancer Therapies; Strategic Deal Targets Radiotherapeutic Supply Chain And Manufacturing

Earnings

Bank of Marin Q2 2025 Adj. EPS $0.29 Misses $0.34 Estimate, Sales $25.912M Miss $27.265M Estimate

JP Morgan analyst Matthew Boss maintains Dillard's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDS#NYSE">DDS</a>) with a Underweight and raises the price target from $368 to $458.

JP Morgan Maintains Underweight on Dillard's, Raises Price Target to $458

FRGT

Freight Technologies Secures Two-Year SaaS Contract With Salzillo To License Fleet Rocket TMS

Cantor Fitzgerald analyst Sarah James downgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Overweight to Neutral and lowers the price target from $65 to $38.

Downgrades

Cantor Fitzgerald Downgrades Centene to Neutral, Lowers Price Target to $38

FBLG

FibroBiologics Files Patent Application With USPTO Covering Methods Of Generating Multipotent Cells From Fibroblasts Found In Donor Tissue For Clinical Applications

FLYE

Fly-E Group Regains Nasdaq Compliance

JP Morgan analyst Matthew Boss maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Underweight and raises the price target from $8 to $10.

JP Morgan Maintains Underweight on Kohl's, Raises Price Target to $10

SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) climbed 5.28% during Monday pre-market amid reports that the company is making significant strides in its Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) strategy, nearing a substantial milestone with a recent major acquisition.
What Happened:&nbsp;On Monday, Blockchain analysis platform Lookonchain, in a post on X, disclosed that SharpLink procured 77,210 ETH, valued at roughly $295 million. This acquisition increases the company&#8217;s&nbsp;total Ethereum reserves to 438,017&nbsp;ETH, worth approximately $1.69 billion.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">SharpLink(<a href="https://twitter.com/SharpLinkGaming?ref_src=twsrc%5Etfw">@SharpLinkGaming</a>) bought another 77,210 <a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a>($295M) and currently holds 438,017 <a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a>($1.69B).<a href="https://t.co/143CVq5E6U">https://t.co/143CVq5E6U</a> <a href="https://t.co/Oa4dQ9XFGF">pic.twitter.com/Oa4dQ9XFGF</a>
&mdash; Lookonchain (@lookonchain) <a href="https://twitter.com/lookonchain/status/1949642059046146559?ref_src=twsrc%5Etfw">July 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Although the company has not officially confirmed this latest acquisition, it indicates a strong push towards its 500,000 ETH target. If this happens, this would establish SharpLink as the second-largest known corporate holder of Ethereum, behind only BitMine Immersion, which holds approximately 566,800 ETH worth $2.21 billion.
The newly acquired ETH by SharpLink was staked in batches of 3,200 ETH through Figment, a top provider of institutional staking infrastructure, reported  Arkham Intelligence. This move indicates that SharpLink's Ethereum-centric strategy is aligning with early market signals.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/equities/25/07/46655759/these-3-dividend-yielding-stocks-could-outperform-as-high-fed-rates-spark-4-9-billion-inflows-ex" target="_blank" rel="noreferrer noopener">These 3 Dividend-Yielding Stocks Could Outperform As High Fed Rates Spark $4.9 Billion Inflows: Expert</a>
Why It Matters: This recent purchase is a significant step in SharpLink Gaming&#8217;s Ethereum strategy, which has been a focus of the company&#8217;s recent activities. Just a week before this acquisition, the company announced a 29% increase in its Ethereum holdings, solidifying its position as the world&#8217;s second-largest <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46547582/whats-going-on-with-sharplink-gaming-sbet-stock-today">corporate Ethereum </a>holder. This news led to a surge in the company&#8217;s stock.
However, this strategy has not been without its challenges. Earlier in the month, SharpLink&#8217;s shares took a hit after the company&nbsp;filed to sell an additional <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46500927/sharplink-sbet-shares-plunge-after-filing-to-sell-an-additional-5-billion-in-stock">$5 billion in stock</a>&nbsp;to fund its Ethereum acquisitions. Despite this, the company&#8217;s stock rebounded, and the recent purchase indicates that SharpLink is continuing to pursue its Ethereum strategy.
On the other hand, BitMine Immersion, the current largest known corporate Ethereum holder,&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46614797/bitmine-immersion-shares-rise-after-ethereum-holdings-surpass-2-billion">announced on July 24</a>&nbsp;that its Ethereum holdings had surpassed $2 billion. This news also led to a rise in the company&#8217;s stock, indicating the growing significance of Ethereum holdings in the gaming industry.
READ MORE:
<ul class="wp-block-list">
<li><a href="https://benzinga.com/crypto/cryptocurrency/25/07/46612914/bitcoin-could-go-to-300000-before-great-depression-crisis-traders-argue" target="_blank" rel="noreferrer noopener">Bitcoin Could Go To $300,000 Before &#8216;Great Depression&#8217; Crisis, Traders Argue &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

$ETH

SBET

SharpLink Gaming Stock Climbs Over 5% In Monday Pre-Market: What's Going On?

Textron's Kautex Receives Order From Automotive OEM For Full-BEV Thermoplastic Composite Lower Battery Housing Unit

Press Releases

Catheter Precision, Inc. Announces New Chief Financial Officer

Catheter Precision, Inc.  Announces Initial LockeT Purchase From the University of Tennessee Medical Center

Catheter Precision, Inc.  Announces Definitive Agreement to Acquire PeriKard, LLC

Catheter Precision to Attend the 30th International Atrial Fibrillation Symposium

Catheter Precision, Inc.  Announces The Closing of its Acquisition of PeriKard, LLC

Contracts

Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy

Catheter Precision, Inc.  Announces Fourth Quarter and Full Year 2024 Update and Financial Results

Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results

Comments

Catheter Precision

Noticias

Últimas noticias sobre Catheter Precision (AMEX:VTAK) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL